Trump Drugmaker Investments Soared Under New Law, Dems Say

The trump drugmaker investments at the center of a new congressional report tell a striking story, according to Democrats: after returning to the White House, President Donald Trump’s pharmaceutical stock holdings grew from a maximum reported value of $1.7 million in 2024 to as much as $56.2 million by the end of 2025. The report, released Friday by the minority arm of the Joint Economic Committee, says up to $39.1 million of that was held in companies benefiting from exemptions to Medicare’s drug price negotiation program — carve-outs created by a provision in Republicans’ 2025 tax and spending law.

Purchases Before and After the Law

Committee Democrats’ analysis of Trump’s financial disclosures found his portfolio bought as much as $2.55 million in shares of pharmaceutical companies benefiting from the exemptions on three dates before he signed the legislation in July 2025. That included up to $950,000 in purchases on July 1, 2025 — the day the Senate passed the bill — and as much as $1 million in AbbVie stock in August 2025, after the bill became law.

What the Exemptions Mean for Patients

The report says the policy could leave some Medicare beneficiaries paying thousands of dollars more for certain cancer treatments and other medications than they would have if Medicare had been allowed to negotiate lower prices. Trump has made lowering prescription drug prices a central promise of his health care agenda — a point the report’s authors say sits uneasily alongside a law that shields certain medications from negotiation.

White House Denies Any Ethics Issue

The White House has repeatedly denied any ethics problems and accused Democrats of “attempts to fabricate conflicts of interest.” The report also places the investments in a broader picture of the president’s wealth, saying it has grown through a web of business interests, many of which have benefited from his administration’s policy moves.

Source: MedPage Today